109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
肿瘤转移至肿瘤：乳腺癌转移至 EGFR 外显子 19 突变型肺腺癌伴长期无病生存期
Authors Zhang Y , Hao Y, Yang H, Meng X, Yang S, Wang J, Xie J, Lu P, Ji Y
Received 12 August 2025
Accepted for publication 11 November 2025
Published 19 November 2025 Volume 2025:19 Pages 707—712
DOI https://doi.org/10.2147/BTT.S558828
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Shein-Chung Chow
Yana Zhang,1,2 Yang Hao,1,2 Han Yang,1,2 Xiangli Meng,1 Shanshan Yang,1 Jin Wang,1 Jinling Xie,1 Ping Lu,1,2,* Yinghua Ji1,2,*
1Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453100, People’s Republic of China; 2Department of Life Science Research Center, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453100, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yinghua Ji, Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, No. 88 Jiankang Road, Weihui, Xinxiang, Henan, 453100, People’s Republic of China, Tel +86 0373 4402543, Email 54234317@qq.com Ping Lu, Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, No. 88 Jiankang Road, Weihui, Xinxiang, Henan, 453100, People’s Republic of China, Tel +86 0373 4402106, Email lupingdoctor@126.com
Abstract: Tumor-to-tumor metastasis (TTM) is a rare phenomenon characterized by the metastasis of one malignant tumor into another histologically different tumor. While breast and lung cancers are prevalent among women globally, TTM involving breast cancer metastasizing to lung adenocarcinoma is exceptionally uncommon. Herein, we report a rare case of Luminal B breast cancer metastasizing to EGFR exon 19 deletion-mutated lung adenocarcinoma. The patient achieved prolonged disease-free survival following comprehensive treatment, including surgical resection, chemotherapy, EGFR-tyrosine kinase inhibitor (TKI) therapy, and endocrine therapy. This case highlights the importance of molecular profiling in guiding personalized therapeutic strategies for TTM, particularly when actionable mutations are present.
Keywords: tumor-to-tumor metastasis, breast cancer, lung cancer, EGFR mutation, targeted therapy
1Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453100, People’s Republic of China; 2Department of Life Science Research Center, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453100, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yinghua Ji, Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, No. 88 Jiankang Road, Weihui, Xinxiang, Henan, 453100, People’s Republic of China, Tel +86 0373 4402543, Email 54234317@qq.com Ping Lu, Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, No. 88 Jiankang Road, Weihui, Xinxiang, Henan, 453100, People’s Republic of China, Tel +86 0373 4402106, Email lupingdoctor@126.com
Abstract: Tumor-to-tumor metastasis (TTM) is a rare phenomenon characterized by the metastasis of one malignant tumor into another histologically different tumor. While breast and lung cancers are prevalent among women globally, TTM involving breast cancer metastasizing to lung adenocarcinoma is exceptionally uncommon. Herein, we report a rare case of Luminal B breast cancer metastasizing to EGFR exon 19 deletion-mutated lung adenocarcinoma. The patient achieved prolonged disease-free survival following comprehensive treatment, including surgical resection, chemotherapy, EGFR-tyrosine kinase inhibitor (TKI) therapy, and endocrine therapy. This case highlights the importance of molecular profiling in guiding personalized therapeutic strategies for TTM, particularly when actionable mutations are present.
Keywords: tumor-to-tumor metastasis, breast cancer, lung cancer, EGFR mutation, targeted therapy